{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:09:37Z","timestamp":1778843377708,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T00:00:00Z","timestamp":1740268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH015"],"award-info":[{"award-number":["ZR2023MH015"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.msard.2025.106340","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T11:57:11Z","timestamp":1741262231000},"page":"106340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Rheumatic antibodies may serve as indicators of disease severity, relapse frequency, and ocular involvement in NMOSD patients"],"prefix":"10.1016","volume":"97","author":[{"given":"Mengyu","family":"wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodi","family":"zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongxia","family":"xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pin","family":"wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2025.106340_bib0001","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10072-023-06617-y","article-title":"Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis","volume":"44","author":"Bagherieh","year":"2023","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2025.106340_bib0002","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11926-021-01000-2","article-title":"Neuromyelitis Optica Spectrum Disorders (NMOSD) and connective tissue disease (CTD): an update for the rheumatologist","volume":"23","author":"Cruz","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"issue":"13","key":"10.1016\/j.msard.2025.106340_bib0003","article-title":"Serum and cerebrospinal fluid biomarkers in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disease","volume":"3","author":"Dinoto","year":"2022","journal-title":"Front. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106340_bib0004","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1007\/s10072-023-06952-0","article-title":"The temporal relationship of paraneoplastic aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and breast cancer: a systematic review and meta-analysis","volume":"44","author":"Srichawla","year":"2023","journal-title":"Neurol. Sci."},{"issue":"13","key":"10.1016\/j.msard.2025.106340_bib0005","article-title":"Plasma Complement 3 and Complement 4 are promising biomarkers for distinguishing NMOSD From MOGAD and are associated with the blood-brain-barrier disruption in NMOSD","volume":"11","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"issue":"466","key":"10.1016\/j.msard.2025.106340_bib0006","article-title":"Potential prognostic value of rheumatoid factor in anti-aquaporin 4-immunoglobin G-positive neuromyelitis optica spectrum disorders","volume":"15","author":"Lee","year":"2024","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106340_bib0007","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jocn.2022.12.005","article-title":"Identification of double-stranded DNA in the cerebrospinal fluid of patients with acute neuromyelitis optica spectrum disorder","volume":"107","author":"Yamamoto","year":"2023","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.msard.2025.106340_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103494","article-title":"Clinical significance of anti-SSA\/Ro antibody in Neuromyelitis optica spectrum disorders","volume":"58","author":"Lin","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"382","key":"10.1016\/j.msard.2025.106340_bib0009","article-title":"Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder","volume":"15","author":"Wang","year":"2023","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.msard.2025.106340_bib0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1620\/tjem.2023.J034","article-title":"Time-Dependent Analysis of Sicca Symptoms and Anti-Ro\/SSA and Anti-La\/SSB Antibodies in Patients with AQP4-IgG-Positive neuromyelitis optica spectrum disorder","volume":"260","author":"Akaishi","year":"2023","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.msard.2025.106340_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1128315","article-title":"CNS demyelinating events in primary Sj\u00f6gren's syndrome: A single-center case series on the clinical phenotype","volume":"14","author":"Afzali","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106340_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578151","article-title":"Serum antinuclear antibodies associate with severe disease activity in neuromyelitis optica spectrum disorder","volume":"382","author":"Wang","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106340_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116619","article-title":"Central nervous system-specific antinuclear antibodies in patients with multiple sclerosis","volume":"409","author":"Fujii","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2025.106340_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-249102","article-title":"Multiple autoimmune disorders in a patient with neuromyelitis optica spectrum disorder presenting with rhabdomyolysis","volume":"15","author":"Sharma","year":"2022","journal-title":"BMJ Case Rep."},{"issue":"4","key":"10.1016\/j.msard.2025.106340_bib0015","article-title":"Autoimmune diseases and cancers overlapping with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A systematic review","volume":"8","author":"Molazadeh","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2025.106340_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis\u2014prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106340_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120742","article-title":"Associations between neuromyelitis optica spectrum disorder, Sjogren's syndrome, and conditions with electrolyte disturbances","volume":"452","author":"Akaishi","year":"2023","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2025.106340_bib0018","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMra1904655","article-title":"Neuromyelitis Optica Spectrum Disorder","volume":"387","author":"Wingerchuk","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106340_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1128315","article-title":"CNS demyelinating events in primary Sjogren's syndrome: A single-center case series on the clinical phenotype","volume":"14","author":"Afzali","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106340_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104466","article-title":"A novel association of osmotic demyelination in Sjogren's syndrome prompts revisiting role of aquaporins in CNS demyelinating diseases: A literature review","volume":"69","author":"Sandhya","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106340_bib0021","article-title":"Overlap syndrome of anti-aquaporin 4 positive neuromyelitis optica spectrum disorder and primary Sjogren's syndrome: a systematic review of individual patient data","volume":"27","author":"Prasad","year":"2023","journal-title":"Rheumatol. Int."},{"issue":"2","key":"10.1016\/j.msard.2025.106340_bib0022","first-page":"161","article-title":"Life After Tetra Hit: Anti-NMDAR Encephalitis After HSV Encephalitis in a NMOSD Coexistent with Sjogren's Syndrome","volume":"59","author":"Ayvacio\u011flu \u00c7a\u011fan","year":"2022","journal-title":"Noro Psikiyatr. Ars."},{"issue":"5","key":"10.1016\/j.msard.2025.106340_bib0023","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s10072-023-06611-4","article-title":"Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases","volume":"44","author":"Carnero Contentti","year":"2023","journal-title":"Neurol. Sci."},{"issue":"6","key":"10.1016\/j.msard.2025.106340_bib0024","first-page":"e26138","article-title":"Neuromyelitis optica spectrum disorder and autoimmune rheumatological diseases: a report of two cases and literature review","volume":"14","author":"Faisal","year":"2022","journal-title":"Cureus."},{"issue":"5","key":"10.1016\/j.msard.2025.106340_bib0025","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s00415-020-10377-6","article-title":"Impact of comorbid Sjogren syndrome in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders","volume":"268","author":"Akaishi","year":"2021","journal-title":"J. Neurol."},{"issue":"sup1","key":"10.1016\/j.msard.2025.106340_bib0026","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/00325481.2022.2159205","article-title":"Behcet disease: an undifferentiating and complex vasculitis","volume":"135","author":"Pak","year":"2023","journal-title":"Postgrad. Med."},{"issue":"10431","key":"10.1016\/j.msard.2025.106340_bib0027","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(23)02629-6","article-title":"Behcet's syndrome","volume":"403","author":"Emmi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2025.106340_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105682","article-title":"The diagnostic performance of AI-based algorithms to discriminate between NMOSD and MS using MRI features: A systematic review and meta-analysis","volume":"87","author":"Etemadifar","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2025.106340_bib0029","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11926-021-01000-2","article-title":"Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update For The Rheumatologist","volume":"23","author":"Cruz","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"issue":"2","key":"10.1016\/j.msard.2025.106340_bib0030","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.survophthal.2019.10.004","article-title":"Primary Sjogren's syndrome and the eye","volume":"65","author":"Bjordal","year":"2020","journal-title":"Surv. Ophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2025.106340_bib0031","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.medcli.2022.10.007","article-title":"Sjogren syndrome","volume":"160","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"Med. Clin."},{"issue":"11","key":"10.1016\/j.msard.2025.106340_bib0032","doi-asserted-by":"crossref","first-page":"6425","DOI":"10.1007\/s10072-022-06315-1","article-title":"Hanges of retinal structure and visual function in patients with demyelinating transverse myelitis","volume":"43","author":"Lee","year":"2022","journal-title":"Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825000835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:30:07Z","timestamp":1778841007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825000835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":32,"alternative-id":["S2211034825000835"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106340","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rheumatic antibodies may serve as indicators of disease severity, relapse frequency, and ocular involvement in NMOSD patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106340"}}